E-ISSN 2507-1432
 
2025, Vol: 4, Issue: 2
4 / 2Current Issue ArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles

Original Article
Online Published: 29 May 2025
 


Safety and Tolerability of SGLT2 Inhibitors in HFrEF: A Prospective Study in a Tropical Climate

Ghulam Abbas Shaikh, Samina Yaqoob, Abdul Rafey Ayaz, Amisha Kumari, Muhammad Khizer Molani, Ayesha Azhar, Eisha Nawaz.


Abstract
Background: Heart failure with reduced ejection fraction (HFrEF) is a chronic condition with high morbidity and mortality. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are emerging as a foundational therapy in HFrEF. However, real-world data on their safety and tolerability in tropical climates remain limited.
Objective: This study aimed to evaluate the safety and tolerability of SGLT2 inhibitors among HFrEF patients in Karachi, Pakistan, a city with a hot and humid climate.

Methods: We conducted a prospective cohort study on 100 patients with HFrEF who were taking SGLT2 inhibitors for at least three months. Adverse effects were recorded using standardized questionnaires and clinical evaluations.

Results: The mean patient age was 56 ± 13 years, with 54% male. Overall, 34% of patients reported side effects. The most frequent were postural hypotension and urinary tract infections (13% each), followed by dehydration (10%). Rehospitalization due to worsening heart failure symptoms occurred in 26% of patients during the study period. Despite these adverse effects, 88% of patients remained compliant with treatment.

Conclusion: SGLT2 inhibitors are generally safe and well-tolerated among HFrEF patients in warm, humid climates when used with proactive monitoring. Our findings support their integration into treatment protocols for this patient population.

Key words: Heart failure with reduced ejection fraction (HFrEF), sodium-glucose co-transporter 2 (SGLT2) inhibitors, tolerability, tropical climate, safety.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Ghulam Abbas Shaikh
Articles by Samina Yaqoob
Articles by Abdul Rafey Ayaz
Articles by Amisha Kumari
Articles by Muhammad Khizer Molani
Articles by Ayesha Azhar
Articles by Eisha Nawaz
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Shaikh GA, Yaqoob S, Ayaz AR, Kumari A, Molani MK, Azhar A, Nawaz E. Safety and Tolerability of SGLT2 Inhibitors in HFrEF: A Prospective Study in a Tropical Climate. J Pub Health Comm Med. 2025; 4(2): 45-49. doi:10.5455/JPHCM.20250415090154

Web Style

Shaikh GA, Yaqoob S, Ayaz AR, Kumari A, Molani MK, Azhar A, Nawaz E. Safety and Tolerability of SGLT2 Inhibitors in HFrEF: A Prospective Study in a Tropical Climate. https://www.wisdomgale.com/jphcm/?mno=252751 [Access: June 05, 2025]. doi:10.5455/JPHCM.20250415090154

AMA (American Medical Association) Style

Shaikh GA, Yaqoob S, Ayaz AR, Kumari A, Molani MK, Azhar A, Nawaz E. Safety and Tolerability of SGLT2 Inhibitors in HFrEF: A Prospective Study in a Tropical Climate. J Pub Health Comm Med. 2025; 4(2): 45-49. doi:10.5455/JPHCM.20250415090154


Vancouver/ICMJE Style

Shaikh GA, Yaqoob S, Ayaz AR, Kumari A, Molani MK, Azhar A, Nawaz E. Safety and Tolerability of SGLT2 Inhibitors in HFrEF: A Prospective Study in a Tropical Climate. J Pub Health Comm Med. (2025), [cited June 05, 2025]; 4(2): 45-49. doi:10.5455/JPHCM.20250415090154


Harvard Style

Shaikh, G. A., Yaqoob, . S., Ayaz, . A. R., Kumari, . A., Molani, . M. K., Azhar, . A. & Nawaz, . E. (2025) Safety and Tolerability of SGLT2 Inhibitors in HFrEF: A Prospective Study in a Tropical Climate. J Pub Health Comm Med, 4 (2), 45-49. doi:10.5455/JPHCM.20250415090154


Turabian Style

Shaikh, Ghulam Abbas, Samina Yaqoob, Abdul Rafey Ayaz, Amisha Kumari, Muhammad Khizer Molani, Ayesha Azhar, and Eisha Nawaz. 2025. Safety and Tolerability of SGLT2 Inhibitors in HFrEF: A Prospective Study in a Tropical Climate. Journal of Public Health and Community Medicine, 4 (2), 45-49. doi:10.5455/JPHCM.20250415090154


Chicago Style

Shaikh, Ghulam Abbas, Samina Yaqoob, Abdul Rafey Ayaz, Amisha Kumari, Muhammad Khizer Molani, Ayesha Azhar, and Eisha Nawaz. "Safety and Tolerability of SGLT2 Inhibitors in HFrEF: A Prospective Study in a Tropical Climate." Journal of Public Health and Community Medicine 4 (2025), 45-49. doi:10.5455/JPHCM.20250415090154


MLA (The Modern Language Association) Style

Shaikh, Ghulam Abbas, Samina Yaqoob, Abdul Rafey Ayaz, Amisha Kumari, Muhammad Khizer Molani, Ayesha Azhar, and Eisha Nawaz. "Safety and Tolerability of SGLT2 Inhibitors in HFrEF: A Prospective Study in a Tropical Climate." Journal of Public Health and Community Medicine 4.2 (2025), 45-49. Print. doi:10.5455/JPHCM.20250415090154


APA (American Psychological Association) Style

Shaikh, G. A., Yaqoob, . S., Ayaz, . A. R., Kumari, . A., Molani, . M. K., Azhar, . A. & Nawaz, . E. (2025) Safety and Tolerability of SGLT2 Inhibitors in HFrEF: A Prospective Study in a Tropical Climate. Journal of Public Health and Community Medicine, 4 (2), 45-49. doi:10.5455/JPHCM.20250415090154


Author LoginReviewer LoginAbout PublisherOpen Access PolicyEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesTerms of UseLicense InformationCopyright Information

About Journal of Public Health and Community Medicine

Journal of Public Health and Community Medicine is an international, peer-reviewed, open access journal, providing a platform for advances in basic, tran ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information

Your comments are very important to us

We welcome your ideas, suggestions, comments, or questions. To reach Editorial Board please use one of the methods provided below.
 

Emails:

info@wisdomgale.com
editorinchief@ejmanager.com

Office Address:
WisdomGale Publishing
14 Rue de Grand-Bigard,
1082 Brussels
Belgium
 
We will respond within 48 to 72 hours.
 
Change of address or personal information? Please visit your account at www.ejmanager.com to update your information.